Video

Bevacizumab in the Neoadjuvant Setting of EOC

Transcript:

Bradley J. Monk, MD, FACS, FACOG: We have said that neoadjuvant therapy is common. So, if you wanted to use bevacizumab (Avastin) in the neoadjuvant setting, how do you do that?

Matthew Powell, MD: Well, there is a recent abstract that was presented at the ASCO Annual Meeting last year. It looked at giving bevacizumab with up-front neoadjuvant chemotherapy. The first 3 cycles were with bevacizumab and cytotoxic chemotherapy. At the cycle right before surgery, their interval cytoreduction, they held the bevacizumab and operated on these patients. Results showed a little bit of what they called “improved surgical outcomes,” where they’re more likely to get the disease to go away. Really, there was no difference in progression-free survival and immature overall survival, at this point. I think safety was shown. That’s about all I could say, at this point.

Bradley J. Monk, MD, FACS, FACOG: So, we have some controversy here. Generally, when we do neoadjuvant, we do 3 cycles. If you want to give 3 cycles of bevacizumab, since you don’t give bevacizumab before surgery, the 3 cycles turns into 4. You get 3 of chemotherapy of bevacizumab and then the fourth. Many times, we thought we weren’t prepared to give it on the first cycle. I think that trial shows that you can give bevacizumab right out of the gate. There was controversy that said that if the cancer was on the bowel, we might cause a gastrointestinal perforation. That appears to have not been borne out in this and other clinical trials. So, I don’t think I know whether to give 4 cycles or 3 cycles, and just give 2 cycles of bevacizumab or just to give bevacizumab after the neoadjuvant surgery, which is certainly another option.

Ursula Matulonis, MD: Do you think that the trial—the small phase II randomized trial that has not been published yet—gives you, as a surgeon, enough justification to use bevacizumab in the first cycle?

Bradley J. Monk, MD, FACS, FACOG: That’s a great question. No, but I’ll probably do it anyway.

Shannon N. Westin, MD, MPH: You said you needed 2 trials.

Matthew Powell, MD: I don’t think bevacizumab, in the first cycle, is enough of a problem, in my mind. Our recurrent-disease patients are getting bevacizumab, in their first cycle, all the time.

David O’Malley, MD: So, where is this or was this drug used the most? In metastatic colorectal, stage 4, parenchymal metastases.

They’ve clearly shown that they can perform a liver resection after bevacizumab. They give at least 6 weeks, and up to 12 weeks. So, we published a phase I trial that also looked at this question of bevacizumab in the up-front setting. Again, it’s a phase I trial. It’s a small trial, but we did the exact same thing. We held the bevacizumab. You have to hold the bevacizumab for at least 6 weeks, for the long half-life. I would even encourage clinicians to hold for 8 or more weeks to make sure that’s out. In regard to the question about why bowel perforations are down, we’re a lot smarter about giving it, right? When we were giving it to everybody, we perforated a lot of bowels. The number was as high as 11% in one publication.

Transcript Edited for Clarity

Related Videos
Cedric Pobel, MD
Jennifer Scalici, MD
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.